S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:NVAX

Novavax (NVAX) Stock Price, News & Analysis

$5.29
+0.41 (+8.40%)
(As of 05:32 PM ET)
Today's Range
$4.91
$5.46
50-Day Range
$3.76
$5.40
52-Week Range
$3.53
$11.36
Volume
18.59 million shs
Average Volume
8.58 million shs
Market Capitalization
$628.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

Novavax MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
372.6% Upside
$25.00 Price Target
Short Interest
Bearish
43.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.27
Upright™ Environmental Score
News Sentiment
0.29mentions of Novavax in the last 14 days
Based on 36 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.87) to ($0.40) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.92 out of 5 stars

Medical Sector

214th out of 939 stocks

Biological Products, Except Diagnostic Industry

31st out of 160 stocks

NVAX stock logo

About Novavax Stock (NASDAQ:NVAX)

Novavax Inc is a biotechnology company that focuses on developing vaccines and biological therapies that combat infectious diseases. The company is headquartered in Gaithersburg, Maryland and has several locations across the United States and Europe. Novavax has a strong track record of developing novel vaccine candidates and has achieved significant milestones in recent years.

In 2020 the company redirected all efforts into finding a vaccine for the COVID-19 pandemic releasing its NVX-CoV2373 vaccine called Nuvaxovid, which has been approved for use in the European Union and Canada. 

Novavax Inc's team is led by CEO John C. Jacobs, who was appointed CEO and board member in Q1 of 2023. Mr. Jacobs has over 25 years of commercial and business operation skills and has demonstrated leadership across multiple therapeutic areas. Mr. Jacobs previously served as CEO and board member at Harmony Biosciences, where he served for five years, leading that company through a successful initial public offering (IPO).

Other notable team members include Dr. Gregory Glenn, the President of Research and Development, with 28 years of vaccine design and regulatory experience. Also noteworthy is Dr. Filip Dubovsky, Novavax Inc's Executive Vice President and Chief Medical Officer, a recognized leader in vaccine development and who joined the company after a 15-year tenure at AstraZeneca, another leading vaccine manufacturer. 

Over the past few years, Novavax has reported steady revenue growth. The company's revenue has increased year over year, reporting net income up each year since 2021. The company's debt levels are high, with total liabilities exceeding total assets for multiple years. Novavax's valuation metrics are in line with industry peers. The company's price-to-earnings ratio and the company's price-to-book ratio are in line with industry peers.

These metrics suggest that the market is valuing Novavax appropriately. Novavax's stock performance has been volatile in recent years. The company's stock price increased significantly in 2020 due to its COVID-19 vaccine development efforts. However, the stock price has since declined, as Novavax has faced delays in obtaining regulatory approvals for its COVID-19 vaccine. Despite these setbacks, the company's long-term prospects remain strong.

The vaccine industry is highly competitive and has significant regulatory and political risks. Novavax faces competition from established pharmaceutical companies, as well as other biotechnology companies that are developing vaccines. However, the company's focus on innovative vaccine candidates, such as its COVID-19 vaccine, gives it a competitive advantage. The vaccine industry is also subject to regulatory risks, as government policy changes can significantly impact the market. Novavax's strong relationships with regulatory agencies give it an advantage in navigating this challenging environment.

Novavax has several growth opportunities in the near term. The company's COVID-19 vaccine has shown promising results in clinical trials and has received regulatory approval in multiple markets. Novavax also has several other vaccine candidates in development, including respiratory syncytial virus (RSV) and influenza vaccines. The company's pipeline of innovative vaccine candidates positions it for long-term growth and success.

Novavax faces several risks and challenges that could impact its long-term success. The company's vaccine candidates are subject to regulatory approval, which can be lengthy and expensive. Novavax also faces significant competition from established pharmaceutical companies and other biotechnology companies. Changes in consumer preferences or shifts in government policies could also impact the market for Novavax's products. 

NVAX Stock Price History

NVAX Stock News Headlines

Novavax’s dispute resolution and upcoming earnings call
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer.
Discover Lexagene - Open to Accredited Investors Only
Get access to significant growth potential in a rapidly scaling biopharma market
Novavax stock surges after resolving Gavi vaccine dispute
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Novavax Shares Surge 28% on Settlement with Gavi
Novavax stock rises on Covid vaccine dispute settlement
Novavax resolves Gavi dispute over COVID-19 vaccines
Better Bull Market Buy: Novavax vs. Pfizer
Better Bull Market Buy: Novavax vs. Pfizer
See More Headlines
Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
2/23/2024
Next Earnings (Confirmed)
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NVAX
CUSIP
67000210
Employees
1,992
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$35.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+369.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-657,940,000.00
Pretax Margin
-52.47%

Debt

Sales & Book Value

Annual Sales
$1.98 billion
Book Value
($8.08) per share

Miscellaneous

Free Float
117,721,000
Market Cap
$633.15 million
Optionable
Optionable
Beta
1.47

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. John Joseph Trizzino B.S. (Age 64)
    M.B.A., President & COO
    Comp: $641.22k
  • Mr. James Patrick Kelly C.F.A. (Age 58)
    Executive VP, CFO & Treasurer
    Comp: $644.32k
  • Mr. Stanley Charles Erck (Age 76)
    Advisor
    Comp: $1.09M
  • Mr. John Charles Jacobs M.B.A. (Age 57)
    CEO & Director
  • Mr. Richard P. Crowley (Age 67)
    Executive VP & COO
  • Mr. Troy Morgan Esq. (Age 53)
    J.D., Senior VP & Chief Compliance Officer
  • Mr. Mark Casey
    Executive VP, Chief Legal Officer & Corporate Secretary
  • Ms. Erika S. Trahan
    Associate Director of Investor & Public Relations
  • Mr. Ian J. Watkins (Age 61)
    Executive VP & Chief Human Resources Officer
  • Ms. Silvia Taylor M.B.A.
    Executive VP and Chief Corporate Affairs & Advocacy Officer














NVAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Novavax stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NVAX shares.
View NVAX analyst ratings
or view top-rated stocks.

What is Novavax's stock price target for 2024?

3 brokers have issued 1-year price targets for Novavax's stock. Their NVAX share price targets range from $15.00 to $35.00. On average, they expect the company's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 372.6% from the stock's current price.
View analysts price targets for NVAX
or view top-rated stocks among Wall Street analysts.

How have NVAX shares performed in 2024?

Novavax's stock was trading at $4.80 on January 1st, 2024. Since then, NVAX shares have increased by 10.2% and is now trading at $5.29.
View the best growth stocks for 2024 here
.

When is Novavax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our NVAX earnings forecast
.

How can I listen to Novavax's earnings call?

Novavax will be holding an earnings conference call on Wednesday, February 28th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 416-764-8677 with passcode "789473 #".

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) announced its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $1.82. The biopharmaceutical company earned $424.40 million during the quarter, compared to analysts' expectations of $264.16 million. The company's quarterly revenue was up 128.3% on a year-over-year basis. During the same period last year, the firm earned ($6.53) EPS.

When did Novavax's stock split?

Shares of Novavax reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What guidance has Novavax issued on next quarter's earnings?

Novavax updated its first quarter 2024 earnings guidance on Monday, December, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $300.0 million-$300.0 million, compared to the consensus revenue estimate of $648.3 million.

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

Who are Novavax's major shareholders?

Novavax's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (12.26%), Shah Capital Management (6.55%), Rafferty Asset Management LLC (1.36%), Coatue Management LLC (1.28%), TSP Capital Management Group LLC (0.94%) and Northern Trust Corp (0.84%). Insiders that own company stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends
.

How do I buy shares of Novavax?

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NVAX) was last updated on 2/23/2024 by MarketBeat.com Staff

From Our Partners